P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)

View/Open

Supporting information (63.31Kb)

Publication Date

2017-01

ICR Author

Marsden,

Author

Popat, S

Hughes, L

O'Brien, M

Ahmad, T

Lewanski, C

Dernedde, U

Jankowska, P

Mulatero, C

Shah, R

Hicks, J

Geldart, T

Cominos, M

Gray, G

Spicer, J

Bell, K

Ngai, Y

Hackshaw, A

Type

Journal Article

Metadata

Show full item record

URL

https://repository.icr.ac.uk/handle/internal/1430

Collections

• Other ICR Research

Version of record

10.1016/j.jtho.2016.11.1713

Language

eng

License start date

2017-01

Citation

Journal of Thoracic Oncology, 2017, 12 (1), pp. S1215 - S1216

Publisher

Elsevier BV